Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

NCT01222767 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT01222767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01222767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
Lead sponsor
PharmaMar
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2010
Completion date
April 30, 2012
Enrollment
17 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

askin's tumor of the chest wall, ewing's sarcoma, extraosseous ewing's sarcoma (eoe), primitive neuroectodermal tumor (pnet)